整合素作为血管及相关疾病的药物靶点
Integrins as Drug Targets in Vascular and Related Diseases.
作者信息
Meredith Emily, Schwartz Martin A
机构信息
Yale Cardiovascular Research Center, Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, Connecticut 06511, USA.
Department of Cell Biology, Yale School of Medicine.
出版信息
Int J Drug Discov Pharm. 2024 Jun;3(2). doi: 10.53941/ijddp.2024.100010. Epub 2024 Jun 21.
Abstract
Integrins are transmembrane receptors that, as critical participants in a vast range of pathological processes, are potential therapeutic targets. However, in only a few cases has the promise been realized by drug approval. In this review, we briefly review basic integrin biology and participation in disease, challenges in the development of safe, effective integrin-targeted therapies, and recent advances that may lead to progress.
摘要
整合素是跨膜受体，作为众多病理过程的关键参与者，是潜在的治疗靶点。然而，只有少数情况下这一前景通过药物获批得以实现。在本综述中，我们简要回顾整合素的基础生物学及其在疾病中的作用、开发安全有效的整合素靶向疗法所面临的挑战，以及可能带来进展的最新研究成果。
相似文献
1
Integrins as Drug Targets in Vascular and Related Diseases.
Int J Drug Discov Pharm. 2024 Jun;3(2). doi: 10.53941/ijddp.2024.100010. Epub 2024 Jun 21.
2
Integrins in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Opportunities.
Biomolecules. 2025 Feb 6;15(2):233. doi: 10.3390/biom15020233.
3
Integrin targeted therapeutics.
Theranostics. 2011 Feb 17;1:154-88. doi: 10.7150/thno/v01p0154.
4
Insights into Protein-Ligand Interactions in Integrin Complexes: Advances in Structure Determinations.
J Med Chem. 2020 Jun 11;63(11):5675-5696. doi: 10.1021/acs.jmedchem.9b01869. Epub 2020 Feb 13.
5
Vascular integrins in tumor angiogenesis: mediators and therapeutic targets.
Endothelium. 2006 Mar-Apr;13(2):113-35. doi: 10.1080/10623320600698037.
6
Targeting integrin pathways: mechanisms and advances in therapy.
Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6.
7
Integrins in cancer: Emerging mechanisms and therapeutic opportunities.
Pharmacol Ther. 2023 Jul;247:108458. doi: 10.1016/j.pharmthera.2023.108458. Epub 2023 May 27.
8
Integrins as therapeutic targets: lessons and opportunities.
Nat Rev Drug Discov. 2010 Oct;9(10):804-20. doi: 10.1038/nrd3266.
9
Integrins as therapeutic targets.
Trends Pharmacol Sci. 2012 Jul;33(7):405-12. doi: 10.1016/j.tips.2012.04.002. Epub 2012 May 25.
10
Integrins: novel therapeutic targets for cardiovascular diseases.
Cardiovasc Hematol Agents Med Chem. 2007 Apr;5(2):109-32. doi: 10.2174/187152507780363223.
引用本文的文献
1
Integrins in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Opportunities.
Biomolecules. 2025 Feb 6;15(2):233. doi: 10.3390/biom15020233.
本文引用的文献
1
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing.
Nature. 2024 Mar;627(8003):416-423. doi: 10.1038/s41586-024-07087-8. Epub 2024 Feb 28.
2
Family-wide analysis of integrin structures predicted by AlphaFold2.
Comput Struct Biotechnol J. 2023 Sep 18;21:4497-4507. doi: 10.1016/j.csbj.2023.09.022. eCollection 2023.
3
Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: a nationwide retrospective study.
J Neurol. 2024 Jan;271(1):374-385. doi: 10.1007/s00415-023-11924-7. Epub 2023 Sep 20.
4
Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy.
Sci Rep. 2023 Aug 31;13(1):14291. doi: 10.1038/s41598-023-41147-9.
5
Challenges in the Development and Application of Organ-on-Chips for Intranasal Drug Delivery Studies.
Pharmaceutics. 2023 May 22;15(5):1557. doi: 10.3390/pharmaceutics15051557.
6
Combined application of biosponges and an antifibrotic agent for the treatment of volumetric muscle loss.
Am J Physiol Cell Physiol. 2023 Jun 1;324(6):C1341-C1352. doi: 10.1152/ajpcell.00092.2023. Epub 2023 May 15.
7
Advanced pathophysiology mimicking lung models for accelerated drug discovery.
Biomater Res. 2023 Apr 26;27(1):35. doi: 10.1186/s40824-023-00366-x.
8
Lineage-Specific Induced Pluripotent Stem Cell-Derived Smooth Muscle Cell Modeling Predicts Integrin Alpha-V Antagonism Reduces Aortic Root Aneurysm Formation in Marfan Syndrome Mice.
Arterioscler Thromb Vasc Biol. 2023 Jul;43(7):1134-1153. doi: 10.1161/ATVBAHA.122.318448. Epub 2023 Apr 20.
9
Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR).
J Neurol. 2023 Aug;270(8):3779-3786. doi: 10.1007/s00415-023-11686-2. Epub 2023 Apr 19.
10
FN (Fibronectin)-Integrin α5 Signaling Promotes Thoracic Aortic Aneurysm in a Mouse Model of Marfan Syndrome.
Arterioscler Thromb Vasc Biol. 2023 May;43(5):e132-e150. doi: 10.1161/ATVBAHA.123.319120. Epub 2023 Mar 30.
Zotero 插件